Last updated: September 21, 2026
[Key Takeaways]
- Many common STIs, including chlamydia and gonorrhea, frequently cause no noticeable symptoms, which means people can carry and transmit an infection without knowing it.
- An absence of symptoms does not mean an absence of risk — transmission to partners and long-term complications such as pelvic inflammatory disease (PID), infertility, and increased HIV susceptibility can still occur.
- The common belief "I'd know if something was wrong" is a misconception rooted in flawed assumptions about risk, partners, and symptom visibility.
- Public health guidance outlines specific screening intervals for sexually active women, men who have sex with men (MSM), pregnant individuals, and people with new or multiple partners.
- Condoms, vaccination (for HPV and hepatitis B), and open communication with partners are useful prevention tools, but they work best alongside — not instead of — routine screening.
It is written in the hope that it can be of even a little help to many readers.
Overview
Sexually transmitted infections (STIs) are often thought of as conditions that announce themselves: a rash, discharge, or discomfort that prompts a visit to the doctor. In reality, a large share of STIs, particularly among women in several studies, tend to produce no noticeable symptoms in many people who carry them.[1] This gap between infection and awareness is one of the main reasons STIs continue to spread and why routine screening, rather than symptom-watching, is considered the more reliable approach to early detection. This article looks at why certain STIs so often go unnoticed, what risks remain even without symptoms, and what current screening guidance recommends for different groups.
[1] Fortas et al., PLOS Glob Public Health (2024)
Table of Contents
STIs and the Silent Symptom Problem
A sexually transmitted infection (STI) is any infection passed primarily through sexual contact, including bacterial infections like chlamydia and gonorrhea, viral infections like herpes simplex virus (HSV), human papillomavirus (HPV), and HIV, and parasitic infections like trichomoniasis. One detail that often surprises people is how rarely many of these infections produce obvious warning signs. A substantial share of chlamydia and gonorrhea infections, for example, produce no symptoms that the infected person notices, particularly in women.[1] This "silent" pattern is not the exception. For several common STIs, it is closer to the norm, which is a major reason public health guidance leans so heavily on scheduled testing rather than symptom-based decision-making.
[1] Fortas et al., PLOS Glob Public Health (2024)
Why Certain STIs Rarely Cause Noticeable Symptoms
The reasons a given STI tends to stay under the radar vary by pathogen, infection site, and the body's immune response:
- Chlamydia and gonorrhea frequently infect the cervix in women or the rectum and throat in any sex, areas where mild inflammation may not be felt or seen the way a urethral infection in men might be.[1]
- Herpes simplex virus (HSV) can shed on the skin's surface without producing a visible sore, a phenomenon known as asymptomatic or subclinical shedding, which still carries a risk of transmission.[2]
- Human papillomavirus (HPV) rarely causes any visible sign at all; most infections are cleared by the immune system over time without ever being noticed.[3]
- Trichomoniasis often produces mild or no symptoms, especially in men, even though the infection can still be passed to partners.[4]
- HIV may cause a brief flu-like illness shortly after exposure, but many people experience no distinct symptoms, and the infection can remain clinically silent for years while still being transmissible.[5]
[1] Chan et al., Infect Dis Obstet Gynecol (2016)
[2] Tronstein et al., JAMA (2011)
[3] Ho et al., N Engl J Med (1998)
[4] Van Gerwen et al., Clin Infect Dis (2021)
[5] Siliciano & Greene, Cold Spring Harb Perspect Med (2011)
Because incubation periods, infection sites, and individual immune responses differ so widely, it is difficult to rely on how a person feels as an indicator of whether an STI is present.
Why "No Symptoms" Doesn't Mean "No Risk"
An infection that produces no symptoms can still be passed to a sexual partner, and it can still affect the body over time. The absence of visible signs says nothing about whether the bacteria or virus is present and active. It only means the infected person has not noticed anything unusual. This is why the assumption that "no symptoms equals no risk" does not hold up: transmission risk is tied to the presence of the pathogen, not to how the infected person feels.
Potential Long-Term Complications If Left Undiagnosed
When common STIs go undiagnosed for an extended period, a number of complications have been associated with them in research and clinical guidance:
- Untreated chlamydia and gonorrhea in women are associated with a higher likelihood of pelvic inflammatory disease (PID), which in turn is linked to an increased risk of infertility, chronic pelvic pain, and ectopic pregnancy.[1]
- Some untreated STIs, including gonorrhea and chlamydia, are associated with a greater likelihood of acquiring or transmitting HIV if exposed, likely related to inflammation and changes to mucosal tissue.[2]
- Persistent infection with certain high-risk HPV types is associated with an increased risk of cervical, anal, and oropharyngeal cancers over time.[3]
[1] den Heijer et al., Clin Infect Dis (2019); Davies et al., Lancet Infect Dis (2016)
[2] Johnson & Lewis, Sex Transm Dis (2008)
[3] Senkomago et al., CDC MMWR (2019); Zhang et al., Signal Transduct Target Ther (2025)
※ Severe pelvic or abdominal pain, especially when it occurs together with fever, is not something to simply wait out — prompt medical evaluation is advised, since it may signal a complication such as PID that benefits from timely care.
The Common Misconception: "I'd Know If Something Was Wrong"
One of the most persistent myths around sexual health is the belief that a person would simply "know" if they had an STI, that some symptom would eventually show up and prompt a trip to the doctor. This assumption tends to form for a few understandable reasons. Many people assume that if a partner were infected, that partner would also notice symptoms and mention it, when in fact a partner may be just as unaware. Others assume they are not "at risk" because they see themselves as being in a stable relationship or not part of a group they associate with higher STI rates, even though risk is tied to exposure history rather than self-perception. Stigma also plays a role: discomfort with discussing sexual health, fear of a positive result, or embarrassment about testing can lead people to avoid the conversation altogether, reinforcing the false comfort of "no symptoms, so no problem."
Why Regular STI Screening Matters
Because so many STIs can be present without producing symptoms, screening on a routine schedule, rather than waiting for a symptom to appear, is the approach recommended by major public health authorities. The Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) both publish screening recommendations aimed at catching infections that would otherwise go unnoticed, allowing for earlier medical attention and reducing the window during which an infection could be unknowingly passed to a partner.[1] Screening does not rely on the patient correctly guessing whether something feels "off"; it is built specifically to catch what symptoms would miss.
[1] USPSTF Chlamydia and Gonorrhea Screening Recommendation (2021); CDC STI Treatment Guidelines, Screening Recommendations
Who Should Get Tested and How Often
Recommended screening frequency varies by group, sexual activity, and individual risk factors. Current guidance generally outlines the following patterns:[1]
[1] USPSTF Chlamydia and Gonorrhea Screening Recommendation (2021); CDC STI Treatment Guidelines, MSM; CDC Prenatal Screening Recommendations; ACOG Practice Advisory, Syphilis in Pregnancy (2024); ACOG Committee Opinion, Prenatal and Perinatal HIV Testing (2018)
| Group | General Screening Guidance |
|---|---|
| Sexually active women under 25 | Annual chlamydia and gonorrhea screening is generally recommended |
| Women 25 and older with risk factors | Annual screening is generally recommended if there are new or multiple partners |
| Men who have sex with men (MSM) | Screening at least annually, with testing every 3 to 6 months suggested for those with multiple or anonymous partners |
| Pregnant individuals | Screening for HIV, syphilis, hepatitis B, and chlamydia is generally recommended as part of prenatal care |
| New or multiple recent partners | Testing is generally recommended before or shortly after a new sexual relationship begins |
These are general patterns rather than a personalized plan. Individual recommendations can vary based on health history, so discussing an appropriate testing schedule with a healthcare provider is advisable.
What an STI Screening Actually Involves
One barrier that keeps people from getting tested is uncertainty about what the process actually looks like. In practice, STI screening is usually less involved than many expect. Depending on which infections are being screened for, it may include a urine sample (commonly used for chlamydia and gonorrhea testing), a blood draw (used for HIV, syphilis, and hepatitis testing), or a swab (which can often be self-collected in a private area rather than requiring a full pelvic exam). Many clinics now offer self-collected vaginal or oral swabs as an option, and rapid HIV tests can sometimes provide results within minutes. None of these steps require the presence of a symptom to be appropriate or useful.
Prevention Strategies to Use Alongside Screening
Screening identifies infections that are already present, while prevention strategies are aimed at reducing the likelihood of exposure in the first place. The two work together rather than substituting for one another. Barrier methods, such as condoms, are associated with a reduced risk of transmission for several STIs when used consistently and correctly, though they do not fully eliminate risk for infections that can spread through skin-to-skin contact, such as HSV or HPV.[1] Vaccination is also a useful tool where available: the HPV vaccine is associated with a reduced risk of infection with the HPV types most strongly linked to cervical and other cancers, and the hepatitis B vaccine can help protect against a virus that is also sexually transmissible.[2] Open communication with partners about testing history and status, while sometimes uncomfortable, is another practical layer of prevention. None of these strategies remove the need for routine screening; they work best as a complement to it, not a replacement.
[1] Winer et al., N Engl J Med (2006); CDC STI Treatment Guidelines, Primary Prevention Methods
[2] Li et al., Epidemiol Infect (2023); Schillie et al., MMWR Recomm Rep (2018)
When and How to Talk to a Healthcare Provider
Bringing up STI testing with a healthcare provider does not require a symptom or a specific concern. A simple, direct request is generally sufficient. Phrases such as "I'd like to be screened for STIs as part of my routine care" or "Can we include STI testing at this visit?" are commonly used and require no further justification. Providers who regularly discuss sexual health are generally accustomed to these requests and can help identify which tests are appropriate based on personal history.
For those who feel uncertain about where to start, options are typically broader than a single primary care visit. Community health centers, public health department clinics, and college or university health services often provide STI testing, and many areas have low-cost or free clinics specifically focused on sexual health for people without insurance or with cost concerns. Some clinics also offer confidential or anonymous testing options for those who prefer additional privacy. Regardless of the setting, the key point remains the same: testing is available on a routine basis, and it does not depend on the presence of a symptom to be worthwhile.
References
- Fortas, C., Delarocque-Astagneau, E., Randremanana, R. V., Crucitti, T., & Huynh, B. T. (2024). "Asymptomatic infections with Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis among women in low- and middle-income countries: A systematic review and meta-analysis." PLOS Global Public Health. https://doi.org/10.1371/journal.pgph.0003226
- Chan, P. A., et al. (2016). "Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature." Infectious Diseases in Obstetrics and Gynecology. https://doi.org/10.1155/2016/5758387
- Tronstein, E., et al. (2011). "Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection." JAMA. https://doi.org/10.1001/jama.2011.420
- Ho, G. Y., et al. (1998). "Natural History of Cervicovaginal Papillomavirus Infection in Young Women." New England Journal of Medicine. https://doi.org/10.1056/NEJM199802123380703
- Van Gerwen, O. T., Camino, A. F., Sharma, J., Kissinger, P. J., & Muzny, C. A. (2021). "Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men." Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab514
- Siliciano, R. F., & Greene, W. C. (2011). "HIV Latency." Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a007096
- den Heijer, C. D. J., et al. (2019). "Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease, Ectopic Pregnancy, and Female Infertility: A Retrospective Cohort Study Among Primary Care Patients." Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciz429
- Davies, B., et al. (2016). "Risk of Reproductive Complications Following Chlamydia Testing: A Population-Based Retrospective Cohort Study in Denmark." The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(16)30092-5
- Johnson, L. F., & Lewis, D. A. (2008). "The Effect of Genital Tract Infections on HIV-1 Shedding in the Genital Tract: A Systematic Review and Meta-Analysis." Sexually Transmitted Diseases. https://pubmed.ncbi.nlm.nih.gov/18685546/
- Senkomago, V., Henley, S. J., Thomas, C. C., Mix, J. M., Markowitz, L. E., & Saraiya, M. (2019). "Human Papillomavirus–Attributable Cancers — United States, 2012–2016." MMWR Morbidity and Mortality Weekly Report, CDC. https://www.cdc.gov/mmwr/volumes/68/wr/mm6833a3.htm
- Zhang, Y., Qiu, K., Ren, J., Zhao, Y., & Cheng, P. (2025). "Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use." Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-02083-w
- U.S. Preventive Services Task Force. (2021). "Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement." https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening
- Centers for Disease Control and Prevention. "STI Treatment Guidelines: Screening Recommendations and Considerations Referenced in Treatment Guidelines." https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm
- Centers for Disease Control and Prevention. "STI Treatment Guidelines: Men Who Have Sex with Men (MSM)." https://www.cdc.gov/std/treatment-guidelines/msm.htm
- Centers for Disease Control and Prevention. "Screening for HIV, STIs, TB, and Hepatitis During Pregnancy." https://www.cdc.gov/pregnancy-hiv-std-tb-hepatitis/php/screening/index.html
- American College of Obstetricians and Gynecologists. (2024). "Screening for Syphilis in Pregnancy." Practice Advisory. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2024/04/screening-for-syphilis-in-pregnancy
- American College of Obstetricians and Gynecologists. (2018). "Prenatal and Perinatal Human Immunodeficiency Virus Testing." Committee Opinion. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/09/prenatal-and-perinatal-human-immunodeficiency-virus-testing
- Winer, R. L., Hughes, J. P., Feng, Q., et al. (2006). "Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women." New England Journal of Medicine. https://doi.org/10.1056/NEJMoa053284
- Centers for Disease Control and Prevention. "STI Treatment Guidelines: Primary Prevention Methods." https://www.cdc.gov/std/treatment-guidelines/clinical-primary.htm
- Li, C., Hall, T. G., Hall, J. J., & He, W. Q. (2023). "Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection." Epidemiology and Infection. https://doi.org/10.1017/S0950268823000213
- Schillie, S., Vellozzi, C., Reingold, A., et al. (2018). "Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices." MMWR Recommendations and Reports, CDC. https://doi.org/10.15585/mmwr.rr6701a1
Comments
Post a Comment